1. Home
  2. Directory
  3. California
  4. Los Angeles
  5. Medical Genetics
  6. NPI Profile
  7. Prescriptions 1275612749

DR. NICOLA LONGO MD
Prescription History 1275612749
Medical Genetics - Clinical Genetics (M.D.) in Los Angeles, CA

NPI Status: Active since November 03, 2006

Contact Information

300 MEDICAL PLAZA SUITE 3100
LOS ANGELES, CA
ZIP 90095
Phone: (310) 301-8732

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. NICOLA LONGO MD, an active Clinical Genetics (M.D.) specialist practicing in Los Angeles, CA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 76 documented patient claims. Among these therapy options, the most frequently utilized medication is Nexviazyme, which accounts for 26 claims alone.

Medication Index

C
G
K
M
N
No matching medications currently found on file.

Carbamazepine

Generic Formulation: CarbamazepineSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills33.8
Peer Average Days Supply946
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,296.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$108.02

State Avg Cost Per Claim

$70.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.

Therapeutic Applications

Carbamazepine is used to prevent and control seizures. This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia). This medication works by reducing the spread of seizure activity in the brain and restoring the normal balance of nerve activity.

Galafold

Generic Formulation: Migalastat HclSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
CA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.5
Peer Average Days Supply378
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $324,033.60 across this reporting matrix range.

Provider Avg Cost Per Claim

$29,457.60

State Avg Cost Per Claim

$29,079.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used for long-term treatment in people with a certain inherited disease (Fabry disease). In Fabry disease, a certain enzyme in your body (alpha-galactosidase) does not work the way it should. This leads to a buildup of a certain fatty substance in your kidneys, heart, and other organs. Migalastat works by helping alpha-galactosidase work better so it can remove the fatty substance. Treatment can decrease some symptoms caused by Fabry disease, such as abdominal cramps, diarrhea, burning pain in the hands and feet, heat intolerance, skin rash, kidney/heart disease, or stroke.

Kuvan

Generic Formulation: Sapropterin DihydrochlorideSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
CA State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.0
Peer Average Days Supply360
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $251,490.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,345.38

State Avg Cost Per Claim

$20,130.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used along with diet changes for long-term treatment of a certain inherited disorder (phenylketonuria-PKU). It helps remove a certain chemical (phenylalanine) from the body. Too much phenylalanine in the body can cause brain damage.

Miglustat

Generic Formulation: MiglustatSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 392
CA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.0
Peer Average Days Supply364
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $12,383.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$884.53

State Avg Cost Per Claim

$1,903.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Miglustat is used for the long-term treatment of a certain rare genetic problem (Gaucher's disease). It works by decreasing the amount of a certain natural fatty substance (glucosylceramide) that builds up due to this condition. This can help improve symptoms of Gaucher's disease, such as tiredness, pain in the joints/bones, and a swollen liver or spleen.

Nexviazyme

Generic Formulation: Avalglucosidase Alfa-NgptSpecialty: Pediatric Medicine
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 364
CA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.0
Peer Average Days Supply301
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 62.5% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,884,236.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$72,470.63

State Avg Cost Per Claim

$65,272.70

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used by people with a certain inherited condition (Pompe disease) to reduce high levels of a certain substance (glycogen) that builds up in the blood. Having high levels of glycogen in the blood may cause muscle weakness, heart problems, and breathing problems. Avalglucosidase alfa works by breaking down glycogen in the blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. NICOLA LONGO MD provides transparency into local medical care patterns within Los Angeles, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Clinical Genetics (M.D.)** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.